Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: A nested case-control study

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 233-239

  Bradley, M C ^a   Murray, L J ^a   Cantwell, M M ^a   Hughes, C M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

GPRD; histamine 2 receptor antagonists; hypergastrinaemia; pancreatic cancer; proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; CASE-CONTROL STUDIES; FEMALE; GREAT BRITAIN; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84855341475     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.511     Document Type: Article

References (56)

1. Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94: 1168-1171 (Pubitemid 34919054)
2. Bateman DN, Colin-Jones D, Hartz S, Langman M, Logan RF, Mant J, Murphy M, Paterson KR, Rowsell R, Thomas S, Vessey M (2003) Mortality study of 18 000 patients treated with omeprazole. Gut 52: 942-946 (Pubitemid 36765283)
3. Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P (2011) Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 22(6): 1420-1426
4. BMJ group (2009) Proton pump inhibitors. In British National Formulary, Section 1.3.5, pp 48-50. RPS publishing, GGP Media: Germany
5. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH (1998) Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 22: 163-169 (Pubitemid 28113376)
6. Brett S (2005) Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 9: 45-50 (Pubitemid 40246770)
7. Caygill CP, Hill MJ, Hall CN, Kirkham JS, Northfield TC (1987) Increased risk of cancer at multiple sites after gastric surgery for peptic ulcer. Gut 28: 924-928 (Pubitemid 17119260)
8. Chao C, Hellmich MR (2010) Gastrin, inflammation, and carcinogenesis. Curr Opin Endocrinol Diabetes Obes 17: 33-39
9. Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J (2006) Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 94: 1107-1115
10. Chu M, Kullman E, Rehfeld JF, Borch K (1997) Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster. Gut 40: 536-540 (Pubitemid 27204937)
11. DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100: 190-200 (Pubitemid 41623288)
12. Farrow DC, Davis S (1990) Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 45: 816-820 (Pubitemid 20179628)
13. Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, Blum A, Bille J, Gonvers JJ, Gyr K (1994) Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35: 23-26 (Pubitemid 24059466)
14. García Rodríguez LA, Pérez Gutthann S (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419-425 (Pubitemid 28227341)
15. García Rodríguez LA, Lagergren J, Lindblad M (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55:1538-1544
16. Heinen MM, Verhage BA, Goldbohm RA, van den Brandt PA (2010) Active and passive smoking and the risk of pancreatic cancer in the Netherlands Cohort Study. Cancer Epidemiol Biomarkers Prev 19(6): 1612-1622
17. Howatson AG, Carter DC (1987) Pancreatic carcinogenesis: effect of secretin in the hamster-nitrosamine model. J Natl Cancer Inst 78: 101-105 (Pubitemid 17019659)
18. IMS Health (2008) Top Therapeutic Classes by US Sales. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/2008-Top-Therapy-Classes-by-U.S.-Sales.pdf (accessed 7 September 2009)
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics 2007. CA Cancer J Clin 57: 43-66
20. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practicioner based computersied data resource in the United Kingdom. BMJ 302: 766-768
21. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium channel blockers and risk of cancer. Lancet 349: 525-528 (Pubitemid 27092790)
22. Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practicioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1: 347-349
23. Kinnear H, Gavin A, Mole D, Ranaghan L (2005) Cancer Services Audit 2001, Pancreas. N Ireland Cancer Registry
24. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Lückers A, Dekkers CP, Havu N, Meuwissen SG (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121: 161-167 (Pubitemid 24225631)
25. La Vecchia C, Negri E, D'Avanzo B, Ferraroni M, Gramenzi A, Savoldelli R, Boyle P, Franceschi S (1990) Medical history, diet and pancreatic cancer. Oncology 47: 463-466 (Pubitemid 20379332)
26. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP (2008) Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 103: 2694-2699
27. Lipworth L, Zucchetto A, Bosetti C, Franceschi S, Talamini R, Serraino D, McLaughlin JK, La Vecchia C, Negri E (2011) Diabetes mellitus, other medical conditions and pancreatic cancer: a case-control study. Diabetes Metab Res Rev 27(3): 255-261
28. Luo J, Nordenvall C, Nyrén O, Adami HO, Permert J, Ye W (2007) The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. Int J Cancer 120: 368-372 (Pubitemid 44956848)
29. National Health Service Business Services Authority (2009) Update on growth of prescription volume and cost in the year to March 2009. Available from: http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/Volume-and-cost- year-to-March-2009.pdf (accessed 21 August 2009)
30. National Institute for Health and Clinical Excellence (2008) The care and management of osteoarthritis in adults. Available at: http://www.nice.org. uk/nicemedia/pdf/CG59NICEguideline.pdf (accessed 21 July 2009)
31. Naunton M, Peterson GM, Bleasel MD (2000) Overuse of proton pump inhibitors. J Clin Pharm Ther 25: 333-340 (Pubitemid 32002877)
32. Parsa I (1987) Invitro carcinogenesis of the pancreas. In Experimental pancreatic cacrcinogenesis, Scarpell, D.G, Reddy, J.K and Longnecker, D.S (eds) CRC press Boca Raton: Florida. 209-232
33. Parsa I, Marsh WH, Sutton AL (1981) An in vitro model of human pancreas carcinogenesis: effects of nitroso compounds. Cancer 47: 1543-1551
34. Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, Friis S (2009) Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer 100: 1503-1507
35. Risch HA (2003) Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95: 948-960 (Pubitemid 36896712)
36. Roberts S, Griffein EP, Harper EA, Hull RAD, Kalindjian SB, Lilley EJ, Kotecha A, Shankley NP, Sykes DA, Watt GF, Black JW (2002) JB95008 (gastrazole), a selective CCK2 receptor (CCK2R) antagonist with in vivo activity. Pharmacologist 44, abstract no. 30.4
37. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT (2007) Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133: 755-760 (Pubitemid 47385871)
38. Rosch PJ (2010) Could proton pump inhibitors cause cancer? Arch Intern Med 170: 1775-1776
39. Sarfati PD, Genik P, Morisset J (1985) Caerulein and secretin induced pancreatic growth: a possible control by endogenous pancreatic somatostatin. Regul Pept 11: 261-273
40. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, Swanson GM, Schwartz AG, Brown LM, Greenberg RS, Schoenberg JB, Pottern LM, Hoover RN, Fraumeni Jr JF (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80: 1830-1837 (Pubitemid 29389642)
41. Smith JP, Fantaskey AP, Liu G, Zagon IS (1995) Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268: 135-141
42. Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS (1994) Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 266: 277-283
43. Stewart D, John D, Cunningham S, McCaig D, Hansford D (2007) A comparison of community pharmacists0 views of over-the-counter omeprazole and simvastatin. Pharmacoepidemiol Drug Saf 16: 1290-1297 (Pubitemid 350303441)
44. Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J, Albanes D (2001) Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93: 937-941 (Pubitemid 32624651)
45. Tascilar M, Van Rees BP, Sturm PD, Tytgat GN, Hruban RH, Goodman SN, Giardiello FM, Offerhaus GJ, Tersmette AC (2002) Pancreatic cancer after remote peptic ulcer surgery. J Clin Pathol 55: 340-345 (Pubitemid 34494171)
46. Tersmette AC, Offerhaus GJ, Giardiello FM, Tersmette KW, Vandenbroucke JP, Tytgat GN (1990) Occurrence of non-gastric cancer in the digestive tract after remote partial gastrectomy: analysis of an Amsterdam cohort. Int J Cancer 46: 792-795
47. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried M (1996) Bacterial overgrowth during treatment with omeprazole compared with cimeti-dine: a prospective randomised double blind study. Gut 39: 54-59 (Pubitemid 26239105)
48. UK Medicines Information Pharmacist groups (2001) New medicines on the market. Available at: http://www.ukmi.nhs.uk/NewMaterial/html/docs/esomep.pdf (accessed 9 August 2009)
49. Van Rees BP, Tascilar M, Hruban RH, Giardiello FM, Tersmette AC, Offerhaus GJ (1999) Remote partial gastrectomy as a risk factor for pancreatic cancer: potential for preventive strategies. Ann Oncol 10(Suppl 4): 204-207
50. van Soest EM, Van Rossum LG, Dieleman JP, Van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ (2008) Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 103: 966-973 (Pubitemid 351501082)
51. Vermeer IT, Engels LG, Pachen DM, Dallinga JW, Kleinjans JC, van Maanen JM (2001) Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole. Gastroenterology 121: 517-525 (Pubitemid 32822565)
52. World Health Organisation Working Group (2008) About the ATC/DDD system, 2009. Available at: http://www.whocc.no/atcddd/atcsystem.html (accessed 22 July 2009)
53. World Health Organisation Working Group (2009) Global Database on Body Mass Index: BMI Classification: WHO 2003. Available at: http://www.who.int/bmi/ index.jsp?introPage intro-3.html (accessed 14 July 2009)
54. Wynn GH, Sandson NB, Cozza KL (2007) Gastrointestinal medications. Psychosomatics 48: 79-85 (Pubitemid 46048032)
55. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133: 748-754 (Pubitemid 47374135)
56. Yeomans ND, Brimblecombe RW, Elder J, Heatley RV, Misiewicz JJ, Northfield TC, Pottage A (1995) Effects of acid suppression on microbial flora of upper gut. Dig Dis Sci 40: 81S-95S